Covered recipient · General Payments record
ROBERT J BUYNAK
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$5,627.38
35 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $3,839.80 | 17 |
| Food and Beverage | $1,787.58 | 18 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $2,690.52 | 10 |
| EISAI INC. | $1,725.98 | 16 |
| Amgen Inc. | $1,114.52 | 8 |
| Gilead Sciences, Inc. | $96.36 | 1 |
Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT J BUYNAK
NPI 1508977984 · CMS profile ID 340544
Allopathic & Osteopathic Physicians / Internal Medicine
VALPARAISO, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
35 matching records · $5,627.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–35 of 35.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk AS | $337.35 | 12/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542047 | CMS |
| Novo Nordisk AS | $193.55 | 12/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542049 | CMS |
| Novo Nordisk AS | $80.53 | 12/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542051 | CMS |
| Novo Nordisk AS | $149.60 | 12/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542053 | CMS |
| Novo Nordisk AS | $274.83 | 12/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703543971 | CMS |
| Gilead Sciences, Inc. | $96.36 | 11/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681487429 | CMS |
| EISAI INC. | $123.81 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697037999 | CMS |
| EISAI INC. | $40.18 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697038001 | CMS |
| EISAI INC. | $405.12 | 06/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048429 | CMS |
| EISAI INC. | $343.80 | 06/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048431 | CMS |
| EISAI INC. | $225.00 | 06/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048433 | CMS |
| EISAI INC. | $57.35 | 06/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048511 | CMS |
| EISAI INC. | $87.00 | 06/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048513 | CMS |
| EISAI INC. | $130.00 | 06/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048515 | CMS |
| EISAI INC. | $71.31 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048517 | CMS |
| EISAI INC. | $38.73 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048519 | CMS |
| EISAI INC. | $22.51 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048521 | CMS |
| EISAI INC. | $46.83 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048523 | CMS |
| EISAI INC. | $23.41 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048525 | CMS |
| EISAI INC. | $45.80 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048527 | CMS |
| EISAI INC. | $23.35 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048529 | CMS |
| EISAI INC. | $41.78 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697048531 | CMS |
| Novo Nordisk AS | $224.87 | 05/14/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542041 | CMS |
| Novo Nordisk AS | $328.48 | 05/14/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542043 | CMS |
| Novo Nordisk AS | $301.31 | 05/14/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542045 | CMS |
| Novo Nordisk AS | $400.00 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703543967 | CMS |
| Novo Nordisk AS | $400.00 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703543969 | CMS |
| Amgen Inc. | $46.23 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344227 | CMS |
| Amgen Inc. | $23.11 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344231 | CMS |
| Amgen Inc. | $46.23 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344233 | CMS |
| Amgen Inc. | $23.11 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344235 | CMS |
| Amgen Inc. | $385.36 | 01/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344217 | CMS |
| Amgen Inc. | $123.88 | 01/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344221 | CMS |
| Amgen Inc. | $304.20 | 01/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344225 | CMS |
| Amgen Inc. | $162.40 | 01/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663344239 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,038,550.53 | 603 |
| PY2024 | Principal investigator | $5,031,915.33 | 601 |
| PY2023 | Recipient | $906.71 | 2 |
| PY2023 | Principal investigator | $4,138,599.32 | 2,384 |
| PY2022 | Recipient | $3,104.59 | 10 |
| PY2022 | Principal investigator | $5,204,363.35 | 1,133 |
| PY2021 | Principal investigator | $3,348,948.64 | 610 |
| PY2020 | Recipient | $1,489.26 | 13 |
| PY2020 | Principal investigator | $1,938,354.41 | 292 |
| PY2019 | Recipient | $658.79 | 10 |
| PY2019 | Principal investigator | $1,439,149.33 | 218 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
305 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,689.33 | 12/31/2020 | Non-covered Recipient Entity Buynak Clinical Research | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736738531 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $62,850.00 | 12/29/2020 | Non-covered Recipient Entity Velocity Clinical Research,Inc | PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years | No dispute reported | 06/30/2026 | 744043575 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 822166403 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,411.00 | 12/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089353 |
| Principal investigator 1 | Janssen Research & Development, LLC | $913,523.00 | 12/22/2020 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | No dispute reported | 06/30/2026 | 719530273 |
| Principal investigator 1 | Novo Nordisk AS | $358.56 | 12/22/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380059 |
| Principal investigator 1 | Novo Nordisk AS | $3,896.46 | 12/22/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380063 |
| Principal investigator 1 | Novo Nordisk AS | $45.00 | 12/21/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 822166405 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,769.40 | 12/18/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664277 |
| Principal investigator 1 | Novo Nordisk AS | $72.00 | 12/18/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 822171817 |
| Principal investigator 1 | PFIZER INC. | $1,495.00 | 12/18/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN | No dispute reported | 06/30/2026 | 742896413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,997.00 | 12/17/2020 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | No dispute reported | 06/30/2026 | 719530271 |
| Principal investigator 1 | PFIZER INC. | $10,500.00 | 12/17/2020 | Non-covered Recipient Entity Velocity Clinical Research Inc | A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN | No dispute reported | 06/30/2026 | 742896411 |
| Principal investigator 1 | PFIZER INC. | $110.89 | 12/08/2020 | Non-covered Recipient Entity Buynak Clinical Research | A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN | No dispute reported | 06/30/2026 | 742900123 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,925.00 | 12/08/2020 | Non-covered Recipient Entity Velocity Clinical Research,Inc | PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years | No dispute reported | 06/30/2026 | 744043535 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,000.00 | 12/03/2020 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | No dispute reported | 06/30/2026 | 719530269 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/02/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 822166399 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/01/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 822166401 |
| Principal investigator 1 | Novo Nordisk AS | $6,514.35 | 11/30/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380061 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184,653.00 | 11/24/2020 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | No dispute reported | 06/30/2026 | 719530267 |
| Principal investigator 1 | Novo Nordisk AS | $1,456.92 | 11/24/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380057 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 11/20/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380041 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,900.00 | 11/17/2020 | Non-covered Recipient Entity Velocity Clinical Research | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 736736205 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $3,002.40 | 11/03/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664273 |
| Principal investigator 1 | Novo Nordisk AS | $12,550.01 | 10/29/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380047 |
| Principal investigator 1 | Novo Nordisk AS | $4,102.92 | 10/29/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380053 |
| Principal investigator 1 | Novo Nordisk AS | $36.00 | 10/26/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,320.00 | 10/15/2020 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | No dispute reported | 06/30/2026 | 719530265 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100,000.00 | 10/14/2020 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | No dispute reported | 06/30/2026 | 719530263 |
| Principal investigator 1 | Eisai Inc. | $23.00 | 10/06/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109193 |
| Principal investigator 1 | Eisai Inc. | $16,082.20 | 10/06/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109229 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $4,932.90 | 10/01/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664267 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/25/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380055 |
| Principal investigator 1 | Novo Nordisk AS | $8,539.92 | 09/24/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380045 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,000.00 | 09/24/2020 | Non-covered Recipient Entity Velocity Clinical Research,Inc | PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years | No dispute reported | 06/30/2026 | 744043461 |
| Principal investigator 1 | Gilead Sciences, Inc. | $879.00 | 09/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089351 |
| Principal investigator 1 | Novo Nordisk AS | $739.80 | 09/22/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380051 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $30,018.00 | 09/01/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EFC-14875 | No dispute reported | 06/30/2026 | 752054301 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 08/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380029 |
| Principal investigator 1 | Novo Nordisk AS | $7,491.42 | 08/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380043 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $2,783.70 | 08/26/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664257 |
| Principal investigator 1 | Novo Nordisk AS | $1,838.16 | 08/25/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380049 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 08/21/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380035 |
| Principal investigator 1 | PFIZER INC. | $34.38 | 08/20/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO | No dispute reported | 06/30/2026 | 742922269 |
| Principal investigator 1 | Eisai Inc. | $15,631.00 | 08/19/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109219 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 08/19/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380033 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 08/14/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380031 |
| Principal investigator 1 | Novo Nordisk AS | $10,203.81 | 07/30/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379849 |
| Principal investigator 1 | Novo Nordisk AS | $358.56 | 07/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379845 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $3,003.30 | 07/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664261 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 07/24/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380039 |
| Principal investigator 1 | Amgen Inc. | $1,350.00 | 07/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH P C | GALACTIC - HF | No dispute reported | 06/30/2026 | 731630787 |
| Principal investigator 1 | Gilead Sciences, Inc. | $65.00 | 07/22/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089349 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 06/26/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379851 |
| Principal investigator 1 | Novo Nordisk AS | $46.36 | 06/26/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379853 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $3,464.10 | 06/25/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664245 |
| Principal investigator 1 | Novo Nordisk AS | $358.56 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379843 |
| Principal investigator 1 | Novo Nordisk AS | $14,475.45 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379847 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379855 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379857 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379859 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379861 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379863 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379865 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379867 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379869 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379871 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379873 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 06/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379875 |
| Principal investigator 1 | PFIZER INC. | $653.32 | 06/18/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO | No dispute reported | 06/30/2026 | 742955239 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,073.00 | 06/17/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089347 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379877 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379879 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379881 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379883 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379885 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379887 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379889 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379891 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379893 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379895 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379897 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379899 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379901 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379903 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379905 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379907 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379909 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379911 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379913 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379915 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379917 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379919 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379921 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379923 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379925 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379927 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379929 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379931 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379933 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379935 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379937 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379939 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379941 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379943 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379945 |
| Principal investigator 1 | Novo Nordisk AS | $12.75 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379947 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379949 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379951 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379953 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379955 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379957 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379959 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379961 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379963 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379965 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379967 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379969 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379971 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379973 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379975 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379977 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379979 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379981 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379983 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379985 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379987 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379989 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379991 |
| Principal investigator 1 | Novo Nordisk AS | $56.90 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379993 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380015 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380017 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380019 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380021 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380023 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380025 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 06/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742380027 |
| Principal investigator 1 | Novo Nordisk AS | $4.90 | 06/11/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380009 |
| Principal investigator 1 | Novo Nordisk AS | $36.00 | 06/11/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380011 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379995 |
| Principal investigator 1 | Novo Nordisk AS | $49.98 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379997 |
| Principal investigator 1 | Novo Nordisk AS | $9.00 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379999 |
| Principal investigator 1 | Novo Nordisk AS | $60.00 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380001 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380003 |
| Principal investigator 1 | Novo Nordisk AS | $9.00 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380005 |
| Principal investigator 1 | Novo Nordisk AS | $36.00 | 06/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380007 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 06/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742380013 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $2,584.80 | 06/01/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664251 |
| Principal investigator 1 | Novo Nordisk AS | $12,133.19 | 05/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379619 |
| Principal investigator 1 | Novo Nordisk AS | $1,203.12 | 05/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379621 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 05/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379839 |
| Principal investigator 1 | PFIZER INC. | $4,117.94 | 05/21/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO | No dispute reported | 06/30/2026 | 742955255 |
| Principal investigator 1 | Novo Nordisk AS | $74.97 | 05/15/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379841 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,358.10 | 05/12/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664241 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,896.30 | 05/01/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664235 |
| Principal investigator 1 | Novo Nordisk AS | $31,737.53 | 04/30/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379617 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 04/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379717 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 04/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379719 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,367.00 | 04/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089345 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 04/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379613 |
| Principal investigator 1 | Novo Nordisk AS | $1,270.00 | 04/23/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379615 |
| Principal investigator 1 | Eisai Inc. | $16,196.40 | 04/22/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109171 |
| Principal investigator 1 | Novo Nordisk AS | $49.98 | 04/17/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379721 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379667 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379669 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379671 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379673 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379675 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379677 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379679 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379681 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379683 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379685 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379687 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379689 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379691 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379693 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379695 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379697 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379699 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379701 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379703 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379705 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379707 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379709 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379711 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379713 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379715 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379723 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379725 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379727 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379729 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379731 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379733 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379735 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379737 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379739 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379741 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379743 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379745 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379747 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379749 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379751 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379753 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379755 |
| Principal investigator 1 | Novo Nordisk AS | $25.50 | 04/07/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379757 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,150.00 | 04/01/2020 | Non-covered Recipient Entity PHARMASEEK LLC | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734918047 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,663.20 | 04/01/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664229 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379665 |
| Principal investigator 1 | Novo Nordisk AS | $972.00 | 03/26/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379629 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 03/26/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO | No dispute reported | 06/30/2026 | 742969059 |
| Principal investigator 1 | Eisai Inc. | $20,883.60 | 03/23/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109143 |
| Principal investigator 1 | Amgen Inc. | $582.00 | 03/21/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | GALACTIC - HF | No dispute reported | 06/30/2026 | 731630775 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,143.00 | 03/18/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089343 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $29,368.80 | 03/18/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664225 |
| Principal investigator 1 | Novo Nordisk AS | $49.98 | 03/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379663 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379633 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379635 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379637 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379639 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379641 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379643 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379645 |
| Principal investigator 1 | Novo Nordisk AS | $1.08 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379647 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379649 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379651 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379653 |
| Principal investigator 1 | Novo Nordisk AS | $30.00 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379655 |
| Principal investigator 1 | Novo Nordisk AS | $3.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379657 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379659 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379661 |
| Principal investigator 1 | Novo Nordisk AS | $16.35 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379759 |
| Principal investigator 1 | Novo Nordisk AS | $9.09 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379761 |
| Principal investigator 1 | Novo Nordisk AS | $23.97 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379763 |
| Principal investigator 1 | Novo Nordisk AS | $108.00 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379765 |
| Principal investigator 1 | Novo Nordisk AS | $8.97 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379767 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379769 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379771 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379773 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379775 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379777 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379779 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379781 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379783 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379785 |
| Principal investigator 1 | Novo Nordisk AS | $16.25 | 03/05/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379787 |
| Principal investigator 1 | Eisai Inc. | $6,668.10 | 02/25/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109173 |
| Principal investigator 1 | Novo Nordisk AS | $1,458.00 | 02/25/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379625 |
| Principal investigator 1 | Novo Nordisk AS | $16,320.00 | 02/25/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379627 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,397.00 | 02/24/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089341 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $22,462.20 | 02/19/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664219 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/19/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379631 |
| Principal investigator 1 | PFIZER INC. | $8,395.53 | 02/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO | No dispute reported | 06/30/2026 | 742968997 |
| Principal investigator 1 | Amgen Inc. | $1,178.91 | 01/29/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | GALACTIC - HF | No dispute reported | 06/30/2026 | 731630779 |
| Principal investigator 1 | Novo Nordisk AS | $432.00 | 01/28/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379623 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,717.00 | 01/27/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH, P.C. | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 742089339 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $9,837.00 | 01/24/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | K-877-302 | No dispute reported | 06/30/2026 | 721664213 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/24/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379837 |
| Recipient | GlaxoSmithKline, LLC. | $69.58 | 01/22/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734914629 |
| Recipient | GlaxoSmithKline, LLC. | $10.00 | 01/22/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734916671 |
| Principal investigator 1 | Eisai Inc. | $15,447.60 | 01/21/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109159 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,406.00 | 01/21/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu | No dispute reported | 06/30/2026 | 744045373 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $295.00 | 01/21/2020 | Non-covered Recipient Entity Valley Research Trials | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu | No dispute reported | 06/30/2026 | 744078867 |
| Principal investigator 1 | Eisai Inc. | $5,000.00 | 01/20/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | No dispute reported | 06/30/2026 | 749109141 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 01/16/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379789 |
| Principal investigator 1 | Romark Laboratories, LC | $100,000.00 | 01/16/2020 | Non-covered Recipient Entity PharmaSeek | Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection | No dispute reported | 06/30/2026 | 750774605 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,828.00 | 01/13/2020 | Non-covered Recipient Entity Buynak Clinical Research PC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu | No dispute reported | 06/30/2026 | 744045411 |
| Principal investigator 1 | Amgen Inc. | $43.81 | 01/09/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | GALACTIC - HF | No dispute reported | 06/30/2026 | 731630783 |
| Principal investigator 1 | Novo Nordisk AS | $9.00 | 01/08/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379815 |
| Principal investigator 1 | Novo Nordisk AS | $72.00 | 01/08/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 742379817 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,514.03 | 01/07/2020 | Non-covered Recipient Entity Buynak Clinical Research | Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) | No dispute reported | 06/30/2026 | 736739895 |
| Recipient | GlaxoSmithKline, LLC. | $349.60 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734899773 |
| Recipient | GlaxoSmithKline, LLC. | $167.89 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734903649 |
| Recipient | GlaxoSmithKline, LLC. | $85.27 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734905119 |
| Recipient | GlaxoSmithKline, LLC. | $72.66 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734905973 |
| Recipient | GlaxoSmithKline, LLC. | $36.54 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734906405 |
| Recipient | GlaxoSmithKline, LLC. | $30.74 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734913615 |
| Recipient | GlaxoSmithKline, LLC. | $24.23 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734913963 |
| Recipient | GlaxoSmithKline, LLC. | $377.06 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734916309 |
| Recipient | GlaxoSmithKline, LLC. | $202.68 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734928321 |
| Recipient | GlaxoSmithKline, LLC. | $32.79 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734928323 |
| Recipient | GlaxoSmithKline, LLC. | $30.22 | 01/07/2020 | Covered Recipient Physician | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 734928401 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379791 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379793 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379795 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379797 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379799 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379801 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379803 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379805 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379807 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379809 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379811 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379813 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379819 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379821 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379823 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379825 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379827 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379829 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379831 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379833 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 01/06/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 742379835 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $48,442.80 | 01/02/2020 | Non-covered Recipient Entity Buynak Clinical Research | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736749297 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,292.40 | 01/02/2020 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C | No dispute reported | 06/30/2026 | 965470793 |